CN114195858B - 多肽及其改造体和在制备抗炎杀菌药物中的应用 - Google Patents
多肽及其改造体和在制备抗炎杀菌药物中的应用 Download PDFInfo
- Publication number
- CN114195858B CN114195858B CN202111359409.9A CN202111359409A CN114195858B CN 114195858 B CN114195858 B CN 114195858B CN 202111359409 A CN202111359409 A CN 202111359409A CN 114195858 B CN114195858 B CN 114195858B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- dmf
- amino acid
- inflammatory
- modified body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 153
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 151
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 151
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims abstract description 15
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims description 6
- 230000000922 anti-bactericidal effect Effects 0.000 title abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 230000004048 modification Effects 0.000 claims description 26
- 238000012986 modification Methods 0.000 claims description 26
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 238000006482 condensation reaction Methods 0.000 claims description 5
- 230000018044 dehydration Effects 0.000 claims description 5
- 238000006297 dehydration reaction Methods 0.000 claims description 5
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 3
- 239000005639 Lauric acid Substances 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 4
- 239000003899 bactericide agent Substances 0.000 claims 4
- 206010061126 Escherichia infection Diseases 0.000 claims 2
- 208000020612 escherichia coli infection Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 33
- 206010040047 Sepsis Diseases 0.000 abstract description 32
- 230000004083 survival effect Effects 0.000 abstract description 30
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract description 9
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract description 9
- 230000003115 biocidal effect Effects 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 4
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000011347 resin Substances 0.000 description 25
- 229920005989 resin Polymers 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- 150000001413 amino acids Chemical group 0.000 description 22
- 238000004128 high performance liquid chromatography Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000005406 washing Methods 0.000 description 15
- 238000000746 purification Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 9
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 238000002784 cytotoxicity assay Methods 0.000 description 9
- 231100000263 cytotoxicity test Toxicity 0.000 description 9
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000009833 condensation Methods 0.000 description 6
- 230000005494 condensation Effects 0.000 description 6
- 239000002173 cutting fluid Substances 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000001376 precipitating effect Effects 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 238000010189 synthetic method Methods 0.000 description 6
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 5
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 5
- -1 Fmoc-Arg (pbf) -OH amino acid Chemical class 0.000 description 5
- 235000021360 Myristic acid Nutrition 0.000 description 5
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 5
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 5
- 238000005086 pumping Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000002924 anti-infective effect Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000000329 molecular dynamics simulation Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 2
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 2
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- IXAYZHCPEYTWHW-IBGZPJMESA-N (2r)-3-tert-butylsulfanyl-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CSC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 IXAYZHCPEYTWHW-IBGZPJMESA-N 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- PNALXAODQKTNLV-JBDRJPRFSA-N Ala-Ile-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O PNALXAODQKTNLV-JBDRJPRFSA-N 0.000 description 1
- DGFXIWKPTDKBLF-AVGNSLFASA-N Arg-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCCN=C(N)N)N DGFXIWKPTDKBLF-AVGNSLFASA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- HKSNHPVETYYJBK-LAEOZQHASA-N Gly-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)CN HKSNHPVETYYJBK-LAEOZQHASA-N 0.000 description 1
- KFQDSSNYWKZFOO-LSJOCFKGSA-N His-Val-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O KFQDSSNYWKZFOO-LSJOCFKGSA-N 0.000 description 1
- RWIKBYVJQAJYDP-BJDJZHNGSA-N Ile-Ala-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN RWIKBYVJQAJYDP-BJDJZHNGSA-N 0.000 description 1
- JDAWAWXGAUZPNJ-ZPFDUUQYSA-N Ile-Glu-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N JDAWAWXGAUZPNJ-ZPFDUUQYSA-N 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- WFCKERTZVCQXKH-KBPBESRZSA-N Leu-Tyr-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O WFCKERTZVCQXKH-KBPBESRZSA-N 0.000 description 1
- CTJUSALVKAWFFU-CIUDSAMLSA-N Lys-Ser-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N CTJUSALVKAWFFU-CIUDSAMLSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- BYIROAKULFFTEK-CIUDSAMLSA-N Ser-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO BYIROAKULFFTEK-CIUDSAMLSA-N 0.000 description 1
- AZGZDDNKFFUDEH-QWRGUYRKSA-N Tyr-Gly-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AZGZDDNKFFUDEH-QWRGUYRKSA-N 0.000 description 1
- ZRSZTKTVPNSUNA-IHRRRGAJSA-N Val-Lys-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(O)=O ZRSZTKTVPNSUNA-IHRRRGAJSA-N 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124425 anti-infective immunomodulator Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (6)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310942039.4A CN117024565A (zh) | 2021-11-17 | 2021-11-17 | 一种多肽改造体及其在制备抗大肠杆菌感染药物中的应用 |
CN202310942038.XA CN117024564A (zh) | 2021-11-17 | 2021-11-17 | 一种多肽改造体及其在制备抗炎杀菌药物中的应用 |
CN202111359409.9A CN114195858B (zh) | 2021-11-17 | 2021-11-17 | 多肽及其改造体和在制备抗炎杀菌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111359409.9A CN114195858B (zh) | 2021-11-17 | 2021-11-17 | 多肽及其改造体和在制备抗炎杀菌药物中的应用 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310942038.XA Division CN117024564A (zh) | 2021-11-17 | 2021-11-17 | 一种多肽改造体及其在制备抗炎杀菌药物中的应用 |
CN202310942039.4A Division CN117024565A (zh) | 2021-11-17 | 2021-11-17 | 一种多肽改造体及其在制备抗大肠杆菌感染药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114195858A CN114195858A (zh) | 2022-03-18 |
CN114195858B true CN114195858B (zh) | 2023-09-08 |
Family
ID=80647801
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310942038.XA Pending CN117024564A (zh) | 2021-11-17 | 2021-11-17 | 一种多肽改造体及其在制备抗炎杀菌药物中的应用 |
CN202310942039.4A Pending CN117024565A (zh) | 2021-11-17 | 2021-11-17 | 一种多肽改造体及其在制备抗大肠杆菌感染药物中的应用 |
CN202111359409.9A Active CN114195858B (zh) | 2021-11-17 | 2021-11-17 | 多肽及其改造体和在制备抗炎杀菌药物中的应用 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310942038.XA Pending CN117024564A (zh) | 2021-11-17 | 2021-11-17 | 一种多肽改造体及其在制备抗炎杀菌药物中的应用 |
CN202310942039.4A Pending CN117024565A (zh) | 2021-11-17 | 2021-11-17 | 一种多肽改造体及其在制备抗大肠杆菌感染药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN117024564A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1838961A (zh) * | 2003-05-30 | 2006-09-27 | 塞诺菲-安万特德国有限公司 | S1p的用途 |
WO2015109112A1 (en) * | 2014-01-16 | 2015-07-23 | Gemmus Pharma Inc. | Combination treatment of antibiotic and gpcr agonist for viral/bacterial co-infections |
CN106344922A (zh) * | 2016-09-14 | 2017-01-25 | 安徽济人药业有限公司 | G蛋白偶联受体18激动剂在制备治疗感染药物中的应用 |
CN107469067A (zh) * | 2017-09-05 | 2017-12-15 | 浙江大学 | 一种多肽及其改造体在制备免疫调节药物中的应用 |
WO2020072700A1 (en) * | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
CN114181293A (zh) * | 2021-12-06 | 2022-03-15 | 郑州大学 | 一种人源抗菌肽ll-37改造体及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006052723A2 (en) * | 2004-11-04 | 2006-05-18 | New England Medical Center Hospitals, Inc. | G protein coupled receptor agonists and antagonists and methods of use |
-
2021
- 2021-11-17 CN CN202310942038.XA patent/CN117024564A/zh active Pending
- 2021-11-17 CN CN202310942039.4A patent/CN117024565A/zh active Pending
- 2021-11-17 CN CN202111359409.9A patent/CN114195858B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1838961A (zh) * | 2003-05-30 | 2006-09-27 | 塞诺菲-安万特德国有限公司 | S1p的用途 |
WO2015109112A1 (en) * | 2014-01-16 | 2015-07-23 | Gemmus Pharma Inc. | Combination treatment of antibiotic and gpcr agonist for viral/bacterial co-infections |
CN106344922A (zh) * | 2016-09-14 | 2017-01-25 | 安徽济人药业有限公司 | G蛋白偶联受体18激动剂在制备治疗感染药物中的应用 |
CN107469067A (zh) * | 2017-09-05 | 2017-12-15 | 浙江大学 | 一种多肽及其改造体在制备免疫调节药物中的应用 |
WO2020072700A1 (en) * | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
CN114181293A (zh) * | 2021-12-06 | 2022-03-15 | 郑州大学 | 一种人源抗菌肽ll-37改造体及其应用 |
Non-Patent Citations (1)
Title |
---|
脓毒症患儿外周血单个核细胞中微小RNA-466和GPR18mRNA的表达及诊断价值;赵杰等;《国际检验医学杂志》;第41卷(第20期);2506-2509 * |
Also Published As
Publication number | Publication date |
---|---|
CN114195858A (zh) | 2022-03-18 |
CN117024565A (zh) | 2023-11-10 |
CN117024564A (zh) | 2023-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104662038B (zh) | 胰高血糖素类似物 | |
CN106632682A (zh) | 融合蛋白ifn-elp及其应用 | |
ES2544573T3 (es) | Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor | |
CN106957356A (zh) | 氯毒素变体、缀合物及其使用方法 | |
CN104530199B (zh) | 一种抗肿瘤多肽及其制备方法和应用 | |
TWI588153B (zh) | 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用 | |
ES2272325T3 (es) | Peptidos contra autoanticuerpos causantes de cmd. | |
CN107051396A (zh) | 一种定点固定蛋白a的免疫吸附材料及其制备方法 | |
KR20190067219A (ko) | 통증 예방, 경감 또는 치료에서의 신경 흥분성 상해 관련 폴리펩타이드의 용도 | |
CN101041693B (zh) | 一种降血糖多肽及其应用 | |
CN100381462C (zh) | 肽及含有所述肽的药物组合物 | |
CN109718363A (zh) | 预防、缓解或治疗阿尔茨海默病的肽及其应用 | |
CN110179994A (zh) | 一种温度和酶双重响应性蛋白质高分子偶联物及其制备方法与应用 | |
CN114195858B (zh) | 多肽及其改造体和在制备抗炎杀菌药物中的应用 | |
ES2197840T3 (es) | Procedimiento para la obtencion y uso de nuevas defensinas humanas como proteinas biologicamente activas para el tratamiento de infecciones y otras enfermedades. | |
CN107805282A (zh) | 一种靶向疗法和免疫疗法联合的多肽 | |
CN101157726A (zh) | 亚血红素短肽化合物及在抗白内障药物制备中的用途 | |
CN109069581A (zh) | 锁环螺旋肽及合成方法 | |
CN110172103A (zh) | GLP-1类似物-Fc融合蛋白及其制备方法和用途 | |
CN107216369A (zh) | 一种鱼精蛋白类似活性肽及其制备方法与应用 | |
CN108295244A (zh) | 用于治疗乳腺肿瘤的多肽 | |
CN100334114C (zh) | 一种新型融合蛋白及其制备 | |
CN101897953A (zh) | 无创性高穿透性表皮生长因子及其应用 | |
JP2012510518A (ja) | 体液貯留障害を処置するための方法および組成物 | |
CN110498860A (zh) | 一种具有抗肿瘤功能的融合蛋白及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220329 Address after: 311400 No. 63 machekan, yewukou village, Xindeng Town, Fuyang City, Hangzhou City, Zhejiang Province Applicant after: Luo Gan Applicant after: Renhao (Hangzhou) biomedical Co.,Ltd. Address before: 311400 No. 63 machekan, yewukou village, Xindeng Town, Fuyang City, Hangzhou City, Zhejiang Province Applicant before: Luo Gan Applicant before: Xu Zhipeng Applicant before: Renhao (Hangzhou) biomedical Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230815 Address after: No. 63 Machekan, Yewukou Village, Xindeng Town, Fuyang District, Hangzhou City, Zhejiang Province, 311400 Applicant after: Luo Gan Applicant after: Xu Zhipeng Applicant after: Renhao (Hangzhou) biomedical Co.,Ltd. Address before: 311400 No. 63 machekan, yewukou village, Xindeng Town, Fuyang City, Hangzhou City, Zhejiang Province Applicant before: Luo Gan Applicant before: Renhao (Hangzhou) biomedical Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |